Literature DB >> 12019114

Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Eric Dannaoui1, Johan W Mouton, Jacques F G M Meis, Paul E Verweij.   

Abstract

Three isolates of zygomycetes belonging to three different genera (Rhizopus microsporus, Absidia corymbifera, and Apophysomyces elegans) were used to produce a disseminated infection in nonimmunocompromised mice. The therapeutic efficacy of amphotericin B, given intraperitoneally at doses ranging from 0.5 to 4.5 mg/kg of body weight/day, oral itraconazole at 100 mg/kg/day, and oral terbinafine at 150 mg/kg/day was evaluated in this model. The markers of antifungal efficacy were the median survival time, the mortality rate, and the percentage of infected organs. Organ culture was performed along with microscopic direct examinations of tissues to assess the presence of an active infection. An acute and lethal infection was obtained in untreated mice challenged with each of the three strains. The data obtained for direct examinations and qualitative cultures indicate that, due to the nonseptate nature of the hyphae, each technique gives different information and should be used together with the others. Against all three strains, amphotericin B yielded a 90 to 100% survival rate. Itraconazole was inactive against R. microsporus but significantly reduced mortality in mice infected with A. corymbifera or A. elegans. Terbinafine had no beneficial effects against R. microsporus and A. corymbifera despite documented absorption of the drug. Overall, only limited correlations were observed between MICs determined in vitro and in vivo efficacy of the drugs. The efficacy of itraconazole in these models of zygomycosis suggests that this drug, as well as the new azole compounds presently under development, warrants close evaluation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019114      PMCID: PMC127262          DOI: 10.1128/AAC.46.6.1953-1959.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Versatile fluorescent staining of fungi in clinical specimens by using the optical brightener Blankophor.

Authors:  R Rüchel; M Schaffrinski
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

2.  Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Acquired itraconazole resistance in Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; M F Monier; M A Piens; S Picot; F Persat
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

4.  An evaluation of the in vitro activity of terbinafine.

Authors:  C J Jessup; N S Ryder; M A Ghannoum
Journal:  Med Mycol       Date:  2000-04       Impact factor: 4.076

5.  Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.

Authors:  E Dannaoui; E Borel; F Persat; M A Piens; S Picot
Journal:  J Med Microbiol       Date:  2000-07       Impact factor: 2.472

Review 6.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

7.  Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.

Authors:  J Mosquera; P A Warn; J L Rodriguez-Tudela; D W Denning
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

8.  Factors determining the susceptibility of mice to experimental phycomycosis.

Authors:  M J Corbel; S M Eades
Journal:  J Med Microbiol       Date:  1975-11       Impact factor: 2.472

9.  Observations on the localization of Absidia corymbifera in vivo.

Authors:  M J Corbel; S M Eades
Journal:  Sabouraudia       Date:  1978-06
View more
  11 in total

1.  In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Authors:  Nikolaos G Almyroudis; Deanna A Sutton; Annette W Fothergill; Michael G Rinaldi; Shimon Kusne
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

Review 2.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

3.  Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.

Authors:  Bianca Schulze; Günter Rambach; Volker U Schwartze; Kerstin Voigt; Katja Schubert; Cornelia Speth; Ilse D Jacobsen
Journal:  Virulence       Date:  2017-08-24       Impact factor: 5.882

4.  First reported case of Gilbertella persicaria in human stool: outcome of a community study from Segamat, Johor, Malaysia.

Authors:  Marie Andrea Laetitia Huët; Li Wen Wong; Calvin Bok Sun Goh; Kuan Shion Ong; Jacky Dwiyanto; Daniel Reidpath; Sui Mae Lee; Sadequr Rahman; Joash Ban Lee Tan
Journal:  Braz J Microbiol       Date:  2020-06-23       Impact factor: 2.476

Review 5.  Zygomycosis: the re-emerging fungal infection.

Authors:  M Chayakulkeeree; M A Ghannoum; J R Perfect
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

6.  Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation.

Authors:  Eric Dannaoui; Patrick Schwarz; Michal Slany; Juergen Loeffler; Anne Tomine Jorde; Manuel Cuenca-Estrella; Philippe M Hauser; Raghdaa Shrief; Michel Huerre; Tomas Freiberger; Peter Gaustad; Juan-Luis Rodriguez-Tudela; Jacques Bille; David W Denning; Stéphane Bretagne; Olivier Lortholary
Journal:  J Clin Microbiol       Date:  2010-04-07       Impact factor: 5.948

7.  Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Authors:  Ana Alastruey-Izquierdo; Maria Victoria Castelli; Isabel Cuesta; Araceli Monzon; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 9.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 10.  Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.

Authors:  Kimberly P Liang; Imad M Tleyjeh; Walter R Wilson; Glenn D Roberts; Zelalem Temesgen
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.